Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.
Compared with no ureteroscopy or percutaneous biopsy, ureteroscopic biopsy in patients with upper tract urothelial carcinoma was significantly associated with a 40% increased risk for intravesical recurrence of disease.
Complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy in patients scheduled to undergo radical cystectomy for muscle-invasive bladder is associated with improved overall and cancer-specific survival, a study found.
Local surgery or ablation may be most appropriate for patients with a solitary site of locoregional recurrence following definitive surgery for clinically localized renal cell carcinoma, according to investigators.
Investigators report findings from the phase 3 CLEAR trial that assessed outcomes with pembrolizumab plus lenvatinib, lenvatinib plus everolimus, or sunitinib in treatment-naive patients with advanced renal cell carcinoma.